The customs duty had about 550 crore estimated impact when the announcements came in July and it is by and large played out to that extent and it is also now completely behind us in the quarter three of FY25. So, going forward that effect will not be there, that was a big dampener on the total margin of the business and of the company.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.